RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Capasso, Domenica ^a   De Paola, Ivan ^b   Liguoro, Annamaria ^c   Del Gatto, Annarita ^b   Di Gaetano, Sonia ^b   Guarnieri, Daniela ^d   Saviano, Michele ^b   Zaccaro, Laura ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c Molecular Diagnostics and Pharmaceuticals Scarl   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAVEOLIN; CLATHRIN; DRUG CARRIER; POLYPEPTIDE; RGDECHI HCIT PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; PEPTIDE; RGDECHI-HCIT PEPTIDE;

ADENOCARCINOMA CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ADHESION; CELL ASSAY; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA CELL LINE; MOLECULAR INTERACTION; PROTEIN EXPRESSION; WM266 CELL LINE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; HELA CELL LINE; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CAVEOLINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLATHRIN; DRUG CARRIERS; HELA CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; NEOPLASM METASTASIS; PEPTIDES;

EID: 84907478626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106441     Document Type: Article

References (56)

1. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
2. Zaccaro L, Del Gatto A, Pedone C, Saviano M (2007) Integrin receptor family: promising target for therapeutic and diagnostic applications. Current Topics in Biochemical Research 9: 45-56.
3. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.
4. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285: 1028-1032.
5. Gladson CL, Cheresh DA (1991) Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. The Journal of clinical investigation 88: 1924-1932.
6. Liapis H, Adler LM, Wick MR, Rader JS (1997) Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human pathology 28: 443-449.
7. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, et al. (1990) Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer research 50: 6757-6764.
8. Zhaofei L (2008) Integrin avb3-Targeted Cancer Therapy. Drug Development Research 69: 329-339.
9. Aguzzi MS, D'Arcangelo D, Giampietri C, Capogrossi MC, Facchiano A (2011) RAM, an RGDS analog, exerts potent anti-melanoma effects in vitro and in vivo. PloS one 6: e25352.
10. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, et al. (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. Journal of experimental & clinical cancer research: CR 27: 86.
11. Zaccaro L, Del Gatto A, Pedone C, Saviano M (2009) Peptides for tumour therapy and diagnosis: current status and future directions. Current medicinal chemistry 16: 780-795.
12. Chen K, Chen X (2011) Integrin targeted delivery of chemotherapeutics. Theranostics 1: 189-200.
13. Millard M, Odde S, Neamati N (2011) Integrin targeted therapeutics. Theranostics 1: 154-188.
14. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, et al. (1999) N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. Journal of medicinal chemistry 42: 3033-3040.
15. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, et al. (2011) Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future oncology 7: 339-354.
16. Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, et al. (2010) Targeting integrins in malignant glioma. Targeted oncology 5: 175-181.
17. Yin AA, Cheng JX, Zhang X, Liu BL (2013) The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical reviews in oncology/ hematology 87: 265-282.
18. Scaringi C, Minniti G, Caporello P, Enrici RM (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer research 32: 4213-4223.
19. Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, et al. (2006) Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. Journal of medicinal chemistry 49: 3416-3420.
20. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, et al. (2009) Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5). Clinical cancer research: an official journal of the American Association for Cancer Research 15: 5224-5233.
21. Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, et al. (2011) Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit. Journal of translational medicine 9: 7.
22. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, et al. (2003) L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer letters 189: 237-247.
23. Haass NK, Smalley KS, Li L, Herlyn M (2005) Adhesion, migration and communication in melanocytes and melanoma. Pigment cell research/ sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 18: 150-159.
24. Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, et al. (1998) Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. British journal of cancer 77: 522-529.
25. McGary EC, Lev DC, Bar-Eli M (2002) Cellular adhesion pathways and metastatic potential of human melanoma. Cancer biology & therapy 1: 459-465.
26. Jilaveanu LB, Aziz SA, Kluger HM (2009) Chemotherapy and biologic therapies for melanoma: do they work? Clinics in dermatology 27: 614-625.
27. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, et al. (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European journal of cancer 46: 270-283.
28. Pisano M, I dP, Nieddu V, Sassu I, Cossu S, et al. (2013) In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells. Anticancer research 33: 871-879.
29. Monfregola L, De Luca S (2011) Synthetic strategy for side chain mono-Nalkylation of Fmoc-amino acids promoted by molecular sieves. Amino acids 41: 981-990.
30. Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Analytical Biochemistry. 159: 109-113.
31. Hansen SH, Sandvig K, van Deurs B (1993) Clathrin and HA2 adaptors: effects of potassium depletion, hypertonic medium, and cytosol acidification. The Journal of cell biology 121: 61-72.
32. Fields CG, Lloyd DH, Macdonald RL, Otteson KM, Noble RL (1991) HBTU activation for automated Fmoc solid-phase peptide synthesis. Peptide research 4: 95-101.
33. Coste J, Le-Nguyen D, Castro B (1990) PyBOP: a new peptide coupling.
34. Reagent devoid of toxic byproduct. Tetrahedron Lett 31: 205-208.
35. Davis GE (1992) Affinity of integrins for damaged extracellular matrix: avb3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Comm 182: 1025-1031.
36. Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, et al. (2000) Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arteriosclerosis, thrombosis, and vascular biology 20: 998-1005.
37. Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell and tissue research 339: 269-280.
38. Seiffert D, Smith JW (1997) The cell adhesion domain in plasma vitronectin is cryptic. The Journal of biological chemistry 272: 13705-13710.
39. Angeletti C, Nichols JW (1998) Dithionite quenching rate measurement of the inside-outside membrane bilayer distribution of 7-nitrobenz-2-oxa-1,3-diazol-4- yl-labeled phospholipids. Biochemistry 37: 15114-15119.
40. De Deyne PG, O'Neill A, Resneck WG, Dmytrenko GM, Pumplin DW, et al. (1998) The vitronectin receptor associates with clathrin-coated membrane domains via the cytoplasmic domain of its beta5 subunit. Journal of cell science 111 (Pt 18): 2729-2740.
41. Alam MR, Dixit V, Kang H, Li ZB, Chen X, et al. (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic acids research 36: 2764-2776.
42. Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, et al. (2006) Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108: 3035-3044.
43. Plow EF, Cierniewski CS, Xiao Z, Haas TA, Byzova TV (2001) AlphaIIbbeta3 and its antagonism at the new millennium. Thrombosis and haemostasis 86: 34-40.
44. Rosenow F, Ossig R, Thormeyer D, Gasmann P, Schluter K, et al. (2008) Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis [corrected]. Neoplasia 10: 168-176.
45. White DE, Muller WJ (2007) Multifaceted roles of integrins in breast cancer metastasis. Journal of mammary gland biology and neoplasia 12: 135-142.
46. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anticancer activity of targeted pro-apoptotic peptides. Nature medicine 5: 1032-1038.
47. Andersen MH, Svane IM, Becker JC, Straten PT (2007) The universal character of the tumor-associated antigen survivin. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 5991-5994.
48. Adderley SR, Fitzgerald DJ (2000) Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. The Journal of biological chemistry 275: 5760-5766.
49. Matsuki K, Sasho T, Nakagawa K, Tahara M, Sugioka K, et al. (2008) RGD peptide-induced cell death of chondrocytes and synovial cells. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association 13: 524-532.
50. Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. Journal of cellular and molecular medicine 9: 360-372.
51. Grossman D, Altieri DC (2001) Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer metastasis reviews 20: 3-11.
52. Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine 222: 124-138.
53. Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, et al. (2013) In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiation oncology 8: 246.
54. Castel S, Pagan R, Mitjans F, Piulats J, Goodman S, et al. (2001) RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Laboratory investigation; a journal of technical methods and pathology 81: 1615-1626.
55. Aguzzi MS, Fortugno P, Giampietri C, Ragone G, Capogrossi MC, et al. (2010) Intracellular targets of RGDS peptide in melanoma cells. Molecular cancer 9: 84.
56. Frisch SM, Ruoslahti E (1997) Integrins and anoikis. Current opinion in cell biology 9: 701-706.